November 18, 2026
Health news, explained with evidence
LIVE

Peptide Immunotherapy Shows Promise in Pediatric Peanut Allergy Trial

🧠 AI Analysis 2 min read 👁 1

A phase II clinical trial indicates that a novel peptide-based monthly shot, PVX108, may safely reduce peanut allergy symptoms in children over a 12-month period.

Peptide Immunotherapy Shows Promise in Pediatric Peanut Allergy Trial🧠AI Analysis

Photo: medpagetoday.com

Key points

  • Phase II trial evaluated PVX108 monthly shots in 71 children aged 4 to 11.
  • Higher dose significantly boosted maximum tolerated peanut dose by 2.4-fold at 12 months.
  • No cases of treatment-related anaphylaxis or severe adverse events were observed.

Novel Peptide Shot Tested in Children

A phase II clinical trial presented at the American College of Allergy, Asthma & Immunology annual meeting suggests that an investigational peptide-based immunotherapy, known as PVX108, may offer a safe and modestly effective approach to reducing peanut allergy symptoms in children. Led by Brian P. Vickery, MD, of Emory University and Children's Healthcare of Atlanta, the study evaluated the monthly intradermal injections in 71 children aged 4 to 11 across trial sites in the U.S. and Australia.

Findings and Safety Profile

For the primary efficacy endpoint, participants receiving the higher dosage of PVX108 experienced a 2.4-fold increase in their maximum tolerated dose of peanut from baseline to month 12, compared with a 1.2-fold change in the placebo group. Furthermore, 39% of patients on the higher dose tolerated at least 300 mg of peanut protein during a one-year oral food challenge, versus 17% of those receiving a placebo. Regarding safety, researchers reported no cases of anaphylaxis or severe adverse events linked to the treatment, with minor local administration site reactions representing the primary side effect.

How the Treatment Works

Unlike standard oral immunotherapy that requires daily consumption of peanut products, PVX108 utilizes short peptide fragments derived from major peanut allergens. According to the study investigators, these fragments are engineered to be too small to interact with immunoglobulin E, thereby avoiding the immediate allergic triggers associated with intact peanut proteins, and instead target T-cells directly. Experts noted that while oral immunotherapy often yields higher tolerance levels, it is frequently accompanied by a higher burden of daily dosing and greater rates of adverse events.

What to know: While the findings suggest potential benefits for children with peanut allergies, the results are currently limited to a phase II trial with a modest sample size. Larger confirmatory studies are needed before broader clinical use. Always consult a qualified healthcare provider for personal medical decisions and allergy management.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/acaai/123923 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.